AZD-3043, a short-acting intravenous anesthetic/sedative agent. This drug was initially invented by Theravance and then developed by AstraZeneca as a positive allosteric modulator of the γ-aminobutyric acid type A (GABA(A)) receptor containing a metabolically labile ester moiety. Phase I clinical trials for use this compound in anesthesia was completed in Sweden and the UK, but further development was discontinued.

ZIRCONIUM ZR-89 is used in specialized diagnostic applications using positron emission tomography (PET). An increasing interest in zirconium-89 can be attributed to the isotope's half-life, which is compatible with antibody imaging. ZR-89 as a radioimmunoconjugate, [89Zr]DFO-HuMab-5B1 was used in preclinical animal models of lung, colorectal, and pancreatic malignancies for PET imaging and was in a phase I trial for pancreatic cancer. In addition, the use of 89Zr-DFO-nimotuzumab that had low organ absorbed dose and effective dose made it suitable for potential human use for immunoPET imaging of epidermal growth factor receptor I. It is known, that epidermal growth factor receptor upregulation is associated with enhanced proliferation and drug resistance in a number of cancers.

Fallypride is a high-affinity antagonist of dopamine D2 and D3 receptors. 18F-radiolabeled fallypride is used as a PET tracer to characterize D2/D3 receptors in the brain.

TAK-960 is a novel, investigational, orally bioavailable, potent, and selective PLK1 inhibitor(IC50=1.5 nM) that has shown activity in several tumor cell lines, including those that express multidrug-resistant protein 1 (MDR1). In animal models, oral administration of TAK-960 increased pHH3 in a dose-dependent manner and significantly inhibited the growth of HT-29 colorectal cancer xenografts. Treatment with once daily TAK-960 exhibited significant efficacy against multiple tumor xenografts, including an adriamycin/paclitaxel-resistant xenograft model and a disseminated leukemia model. TAK-960 had been in phase I clinical trials by Takeda for the treatment of solid tumours. It had also been in preclinical trials for the treatment of acute myeloid leukaemia. However, these studies were discontinued.

GW-870086 (now known as GSK 870086) was developed by GlaxoSmithKline as a glucocorticoid receptor agonist. Repeat inhaled doses of GW-870086 was studied in phase II clinical trial in patients with asthma. In addition, phase II clinical trial was investigated to determine the efficacy of GW-870086 ream formulation in subjects with moderate to severe atopic dermatitis. However, the development of this drug appears to have been discontinued.

Hedaquinium was studied as an antibacterial agent.